| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.1 | 0.06 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.057 | 0.07 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | -0.063 | 0.07 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.06 | 0.07 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.07 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.083 | 0.07 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.058 | 0.08 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.08 |